Liquid Biopsy as a Diagnostic and Prognostic Tool for Women and Female Dogs with Breast Cancer

Autor(es)

Colombo, Jucimara ^[1] ; Moschetta-Pinheiro, Marina Gobbe ^[1] ; Novais, Adriana Alonso ^[1] ; Stoppe, Bruna Ribeiro ^[1] ; Bonini, Enrico Dumbra ^[1] ; Goncalves, Francine Moraes ^[1] ; Fukumasu, Heidge ^[2] ; Coutinho, Luiz Lehmann ^[3] ; de Almeida Chuffa, Luiz Gustavo ^[4] ; Pires de Campos Zuccari, Debora Aparecida ^[1]

Afiliação do(s) autor(es)

^[1] Fac Med Sao Jose, Dept Mol Biol, Lab Mol Invest Canc LIMC, BR-15090000 Sao Jose Do Rio Preto - Brazil

^[2] Univ Sao Paulo, Fac Anim Sci & Food Engn, Dept Vet Med, Lab Comparat & Translat Oncol LOCT, BR-13635900 Pirassununga - Brazil

^[3] Univ Sao Paulo, Luiz de Queiroz Coll Agr ESALQ, BR-13418900 Piracicaba - Brazil

^[4] Univ Estadual Paulista, Inst Biosci Botucatu, Dept Struct & Funct Biol, BR-18618689 Botucatu, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: CANCERS; v. 13, n. 20 OCT 2021.
• Citações Web of Science: 0

Resumo

Simple Summary:\& nbsp;Breast cancer (BC) has common characteristics in women and female dogs, such as high recurrence, metastasis, and mortality rate. In both species, BC prognosis is limited due to its heterogeneous molecular aspects. Although conventional biopsy remains the gold standard for BC diagnosis, liquid biopsy is a very promising tool, especially for patient follow-up. We investigated the effectiveness of liquid biopsy in the diagnosis and follow-up of women and female dogs with BC, using both core biopsy and plasma samples processed by next generation sequencing (NGS) assay. We noted that NGS is a sophisticated technique generating multiple and complex results, which must be validated. Notably, the number of genetic variants increased as the disease progressed. We conclude that liquid biopsy can be considered more effective when performed from the onset of the disease and continues to be applied for monitoring the follow up of BC patients, helping to drive the clinician's decision for medical intervention.</p> \& nbsp;</p> Introduction: Breast cancer (BC) is the malignant neoplasm with the highest mortality rate in women and female dogs are good models to study BC. Objective: We investigated the efficacy of liquid biopsy to detect gene mutations in the diagnosis and follow-up of women and female dogs with BC. Materials and Methods: In this study, 57 and 37 BC samples were collected from women and female dogs, respectively. After core biopsy and plasma samples were collected, the DNA and ctDNA of the tumor fragments and plasma were processed for next generation sequencing (NGS) assay. After preprocessing of the data, they were submitted to the Genome Analysis ToolKit (GATK). Results: In women, 1788 variants were identified in tumor fragments and 221 variants in plasma; 66 variants were simultaneously detected in tumors and plasma. Conversely, in female dogs, 1430 variants were found in plasma and 695 variants in tumor fragments; 59 variants were simultaneously identified in tumors and plasma. The most frequently mutated genes in the tumor fragments of women were USH2A, ATM, and IGF2R; in female dogs, they were USH2A, BRCA2, and RRM2. Plasma of women showed the most frequent genetic variations in the MAP3K1, BRCA1, and GRB7 genes, whereas plasma from female dogs had variations in the NF1, ERBB2, and KRT17 genes. Mutations in the AKT1, PIK3CA, and BRIP genes were associated with tumor recurrence, with a highly pathogenic variant in PIK3CA being particularly prominent. We also detected a gain-of-function mutation in the GRB7, MAP3K1, and MLH1 genes. Conclusion: Liquid biopsy is useful to identify specific genetic variations at the beginning of BC manifestation and may be accompanied over the entire follow-up period, thereby supporting the clinicians in refining interventions.</p> (AU)

• Processo FAPESP: 17/15006-5 - Marcadores tumorais em biópsia líquida: estudo dos mecanismos de resistência por bloqueio do reparo de DNA: análise comparativa
• Beneficiário: Debora Aparecida Pires de Campos Zuccari
• Modalidade de apoio: Auxílio à Pesquisa - Regular